biomArkers to differeNtiate bacTerial From vIral iNfEctions
NCT03163628 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 983
Last updated 2025-12-19
Summary
ANTOINE is a prospective trial which aims to assess diagnostic performance of 7 biomarkers for the diagnosis of severe bacterial infections (SBI) in children aged from 7 days to 36 months.
Fever is a frequent cause of consultation in pediatric emergency departments. Clinical diagnostic tools are rare and discrimination between severe bacterial infection and viral infection is difficult to confidently state. The prevalence of severe bacterial infections (IBS) varies from 10 to 25% according to the studies. Biological markers such as procalcitonin (PCT) and C-reactive protein (CRP) are commonly used in clinical practice. These markers have bacterial specificity but share a wide range of values with viral infections and do not make it possible to exclude or to confirm definitively the diagnosis of IBS. The use of new markers to improve the diagnosis of bacterial and viral infections is increasingly studied in adults. The diagnostic value of these new markers has been demonstrated by associating their dosage with that of CRP for example. This is the case for IP-10, TRAIL or MxA. However, very few pediatric studies have been carried out to date on these new biomarkers. However, in pediatrics, these diagnostic tools based on the combination of biomarkers to discriminate against viral and bacterial infections could be a major help in the suspicions of IBS. 7 biomarkers were selected to be evaluated in this study. This study is designed to determine the best biomarkers combination for the SBI diagnosis on a cohort of 800 patients.
Conditions
- Infection, Bacterial
- Infection Viral
Interventions
- BIOLOGICAL
-
Diagnostic performances of a combination of biomarkers
3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance. The calculation of positive and negative likelihood ratios will be performed. The targeted performances are: * A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5. * A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Yves GILLET, MD · Hospices Civils de Lyon
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 7 Days
- Max Age
- 36 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-06-06
- Primary Completion
- 2019-06-12
- Completion
- 2019-06-12
Countries
- France
Study Locations
More Related Trials
-
Maternal- Fetal Infection
NCT03371056 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
NCT00113191 ·Status: COMPLETED ·Phase: NA
-
Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections
NCT00709358 ·Status: COMPLETED ·Phase: PHASE4
-
Molecular Culture for the Diagnosis of Pediatric Sepsis
NCT06018792 ·Status: RECRUITING
-
Bacteriological Evaluation of Children With Otorrhea
NCT04807660 ·Status: RECRUITING
-
Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines
NCT02590198 ·Status: COMPLETED
-
SeroCovid<19: Covid-19 Seroconversion in Tertiary Pediatric Patients
NCT04615000 ·Status: COMPLETED
-
3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children
NCT05544565 ·Status: RECRUITING ·Phase: PHASE4
-
Lyon Cohort of Maternal and Congenital Toxoplasma Infections
NCT02936921 ·Status: RECRUITING
-
Impact of the Use of CRP on the Prescription of Antibiotics in General Practitioners
NCT03540706 ·Status: COMPLETED ·Phase: NA
-
Interest of the Presepsin Assay as a Biomarker of Bacterial Infection, in the Management of Newborns and Infants Under 3 Months of Age Admitted for Fever in Pediatric Emergency Service (Presepsin)
NCT04076345 ·Status: TERMINATED
-
Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in Children
NCT06852846 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Coronavirus Pediatric Serological Study
NCT05128435 ·Status: COMPLETED
-
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
NCT01446289 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
NCT02527681 ·Status: TERMINATED ·Phase: PHASE1
-
Serocorrelate of Protection Against GBS (PREPARE WP3)
NCT04732026 ·Status: RECRUITING
-
CRP for Respiratory Diagnosis in Kyrgyz Pediatric Practice
NCT05195866 ·Status: COMPLETED ·Phase: NA
-
Covid-19 Rapid Diagnostic Tests on Blood Drop
NCT04467008 ·Status: COMPLETED
-
Detection of Human Cytomegalovirus in the Saliva
NCT00815802 ·Status: COMPLETED
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
NCT06086626 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
NCT07033663 ·Status: RECRUITING
-
Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
NCT05315583 ·Status: TERMINATED ·Phase: NA
-
Microbiome, Antibiotics, and Growth Infant Cohort
NCT03001167 ·Status: COMPLETED
-
Molecular Culture for the Diagnosis of Neonatal Sepsis
NCT05763680 ·Status: UNKNOWN
-
Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19
NCT04355533 ·Status: COMPLETED ·Phase: NA